Cholangiocarcinoma is the primary malignancy arising from the biliary epithelium.The disease is marked by jaundice,cholestasis,and cholangitis.Over 50 percent of patients present with advanced stage disease,precluding...Cholangiocarcinoma is the primary malignancy arising from the biliary epithelium.The disease is marked by jaundice,cholestasis,and cholangitis.Over 50 percent of patients present with advanced stage disease,precluding curative surgical resection as an option of treatment.Prognosis is poor,and survival has been limited even after biliary decompression.Palliative management has become the standard of care for unresectable disease and has evolved to include an endoscopic approach. Photodynamic therapy(PDT)consists of administration of a photosensitizer followed by local irradiation with laser therapy.Several studies conducted in Europe and the United States have shown a marked improvement in the symptoms of cholestasis,survival,and quality of life.This article summarizes the published experience regarding PDT for cholangiocarcinoma and the steps required to administer this therapy safely.展开更多
Background: The radiosensitizing effect of Photofrin II has been demonstrated in vitro and in animal models, even in tumor models known to be highly radioresistant, such as glioblastoma and bladder carcinoma. Radio-ad...Background: The radiosensitizing effect of Photofrin II has been demonstrated in vitro and in animal models, even in tumor models known to be highly radioresistant, such as glioblastoma and bladder carcinoma. Radio-adaptive doses are also known to lead to an augmented cell or tissue reaction. The aim of this study was to investigate potential synergistic or additive effects when combining the two methods in vitro for an improved therapeutic concept in bladder cancer. Material and Methods: RT4 human bladder carcinoma cell line and HCV29 human bladder epithelium cells were seeded and incubated with various concentrations of Photofrin II. The cells were additionally irradiated with ionizing radiation (0.05 Gy/2 Gy/0.05 Gy + 2 Gy). Cells without Photofrin II incubation and irradiation served as controls. The cell survival was evaluated. Results: The survival rate of both cell lines, RT4 and HCV29, did not differ significantly when incubated with a non-toxic concentration of Photofrin II and exposed to a pre-irradiation dose of 0.05 Gy prior to the 2 Gy radiation fraction, compared to cells exposed to Photofrin II plus a 2 Gy ionizing radiation. Conclusion: The combination of both methods did neither demonstrate a synergistic or additive effect nor did it lead to a negative influence of both modulating factors in an in vitro setting.展开更多
被称为现代光动力医学之父的美国Roswell Park癌症研究所(Roswell Park Cancer Institute,RPCI)光动力中心终身主任Thomas J.Dougherty博士于2018年10月不幸病逝。Dougherty在上世纪七十年代研发的Photofrin是全球第一个获得批证的用于...被称为现代光动力医学之父的美国Roswell Park癌症研究所(Roswell Park Cancer Institute,RPCI)光动力中心终身主任Thomas J.Dougherty博士于2018年10月不幸病逝。Dougherty在上世纪七十年代研发的Photofrin是全球第一个获得批证的用于肿瘤光动力疗法的光敏剂,目前仍在欧美和亚洲部分国家和地区使用。他的工作也是现代光动力医学的一个重要里程碑。根据Dougherty本人以及和他共事过的美国同事提供的资料,本文对Dougherty博士和Photofrin研发过程中的一些重要历史人物和事件做一回顾性介绍。展开更多
文摘Cholangiocarcinoma is the primary malignancy arising from the biliary epithelium.The disease is marked by jaundice,cholestasis,and cholangitis.Over 50 percent of patients present with advanced stage disease,precluding curative surgical resection as an option of treatment.Prognosis is poor,and survival has been limited even after biliary decompression.Palliative management has become the standard of care for unresectable disease and has evolved to include an endoscopic approach. Photodynamic therapy(PDT)consists of administration of a photosensitizer followed by local irradiation with laser therapy.Several studies conducted in Europe and the United States have shown a marked improvement in the symptoms of cholestasis,survival,and quality of life.This article summarizes the published experience regarding PDT for cholangiocarcinoma and the steps required to administer this therapy safely.
文摘目的研究光动力学治疗前后肿瘤残腔壁组织细胞凋亡情况,观察光动力学治疗效果,以期为进一步改善临床应用奠定基础。方法手术中在切除或大部分切除胶质瘤之后的肿瘤残腔壁,分别于光动力学治疗(PD T)前后在对应点取少量组织,分别对标本行TU N EL法凋亡细胞免疫组化病理检验及H E染色。结果病理切片共29张,光动力学治疗前16张仅3张出现凋亡细胞,细胞凋亡率平均0.05%;光动力学治疗后的13张均出现了阳性染色细胞,细胞凋亡率平均39.16%。结论Photofrin介导光动力学治疗胶质瘤可以诱导肿瘤细胞的快速凋亡。
文摘Background: The radiosensitizing effect of Photofrin II has been demonstrated in vitro and in animal models, even in tumor models known to be highly radioresistant, such as glioblastoma and bladder carcinoma. Radio-adaptive doses are also known to lead to an augmented cell or tissue reaction. The aim of this study was to investigate potential synergistic or additive effects when combining the two methods in vitro for an improved therapeutic concept in bladder cancer. Material and Methods: RT4 human bladder carcinoma cell line and HCV29 human bladder epithelium cells were seeded and incubated with various concentrations of Photofrin II. The cells were additionally irradiated with ionizing radiation (0.05 Gy/2 Gy/0.05 Gy + 2 Gy). Cells without Photofrin II incubation and irradiation served as controls. The cell survival was evaluated. Results: The survival rate of both cell lines, RT4 and HCV29, did not differ significantly when incubated with a non-toxic concentration of Photofrin II and exposed to a pre-irradiation dose of 0.05 Gy prior to the 2 Gy radiation fraction, compared to cells exposed to Photofrin II plus a 2 Gy ionizing radiation. Conclusion: The combination of both methods did neither demonstrate a synergistic or additive effect nor did it lead to a negative influence of both modulating factors in an in vitro setting.
文摘被称为现代光动力医学之父的美国Roswell Park癌症研究所(Roswell Park Cancer Institute,RPCI)光动力中心终身主任Thomas J.Dougherty博士于2018年10月不幸病逝。Dougherty在上世纪七十年代研发的Photofrin是全球第一个获得批证的用于肿瘤光动力疗法的光敏剂,目前仍在欧美和亚洲部分国家和地区使用。他的工作也是现代光动力医学的一个重要里程碑。根据Dougherty本人以及和他共事过的美国同事提供的资料,本文对Dougherty博士和Photofrin研发过程中的一些重要历史人物和事件做一回顾性介绍。
